EffRx Pharmaceuticals has launched a new effervescent buffered oral solution (70mg), designed for the treatment of osteoporosis, in the US.
The new solution, BINOSTO (alendronate sodium), is intended for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis.
EffRx Pharmaceuticals chairman and CEO Christer Rosen said the company is pleased that its first product, BINOSTO, has been launched in the US by its distribution partner Mission Pharmacal.
"We are stepping into a new business phase and it is very encouraging to get the news from Mission about the positive reaction BINOSTO has received from the healthcare community in the United States," Rosen added.
"With this exciting new treatment option, physicians can rest easily, knowing they are prescribing an easy-to-take and proven therapy for their osteoporosis patients that protects against fracture risk at the hip and spine."
The company has also said that it will regain the rights to BINOSTO / Steovess (EX101) in territories outside of North America.
